Q: What is Eylea used for?

Eylea is used to treat: Neovascular age-related macular degeneration Macular edema Diabetic retinopathy

Q: How does Eylea work?

Blocking Abnormal Vessel Growth Eylea belongs to a class of medications known as vascular endothelial growth factor (VEGF) inhibitors. In certain eye conditions, the body produces high levels of a protein called VEGF. This protein signals the body to create new blood vessels. However, in the eye, these new vessels are often weak and abnormal. These abnormal vessels can leak blood and fluid into the retina, which is the light-sensitive tissue at the back of the eye. This leakage causes swelling and damage, leading to vision loss. The Decoy Mechanism Eylea acts as a decoy receptor or a trap for specific proteins in the eye. It specifically targets and binds to: VEGF-A: The primary protein responsible for new blood vessel growth and increased vascular permeability. PlGF (Placental Growth Factor): Another protein that contributes to the growth of abnormal blood vessels and inflammation. When Eylea binds to these proteins, it prevents them from attaching to their natural receptors on the surface of blood vessel cells. Because the proteins are trapped, they cannot send the signal to grow new vessels or cause existing ones to leak. Reducing Swelling and Fluid By blocking these signals, Eylea helps to: Decrease the amount of fluid and swelling (edema) in the retina. Prevent the formation of new, fragile blood vessels. Stop existing abnormal vessels from leaking. This process helps to stabilize vision and, in many cases, can lead to an improvement in sight by clearing the fluid that interferes with the retina's function.

Q: What are the active ingredients in Eylea?

The active ingredient in Eylea is aflibercept .

Q: What are the side effects of Eylea?

Common side effects of Eylea may include: eye pain conjunctival hemorrhage vitreous floaters Always consult with a healthcare professional about potential side effects.

Q: What drug class is Eylea?

Eylea belongs to the VEGF inhibitor drug class.

Q: What is the dosage of Eylea and how do I take it?

How Eylea is Administered Eylea is given as an intravitreal injection, which means it is injected directly into the vitreous (the jelly-like substance) of the eye. This procedure is performed by a healthcare professional, such as an ophthalmologist, in a clinical setting. Before the injection, your doctor will use local anesthesia to numb the eye and may use antiseptic eye drops to help prevent infection. You may feel some pressure during the procedure, but the numbing medication helps minimize discomfort. Typical Dosing Schedule The frequency of injections depends on the specific eye condition being treated and how well you respond to the medication. In many cases, treatment begins with a series of injections given once every few weeks. After this initial phase, the time between injections may be extended to a maintenance schedule. Your healthcare provider will determine the best schedule for you based on regular eye examinations and imaging tests to monitor the health of your retina. Missed Doses If you miss an appointment for your injection, contact your doctor's office as soon as possible to reschedule. Maintaining a consistent treatment schedule is important for managing your condition effectively.

Q: Is Eylea safe during pregnancy and breastfeeding?

Pregnancy It is not known if Eylea will harm an unborn baby, as there are no adequate and well-controlled studies in pregnant women. However, animal studies involving high doses of the medication administered intravenously showed evidence of embryo-fetal toxicity, including birth defects and pregnancy loss. While the dose used in human eye injections is much lower, the potential risk to a fetus cannot be ruled out. Because of these potential risks, healthcare providers typically recommend that individuals who can become pregnant use effective birth control to prevent pregnancy. Contraception should be used: Before the first injection. During the entire course of treatment. For at least 3 months after the final injection of Eylea. If you become pregnant while receiving this medication, notify your healthcare provider immediately to discuss the risks and benefits of continuing treatment. Breastfeeding It is unknown whether Eylea passes into human breast milk or if it could affect a nursing infant. Because many drugs are excreted in human milk and there is a potential for serious adverse reactions in the infant, a decision must be made whether to discontinue breastfeeding or discontinue the drug. This decision should be made in consultation with a doctor, taking into account the importance of the medication to the mother's health.

Q: What forms and strengths does Eylea come in?

Available Forms Eylea is a sterile solution intended for intravitreal injection, which is a procedure where the medication is injected directly into the eye by a healthcare provider. The medication is provided in the following forms: Single-dose vial: A vial containing the solution for one-time use. Single-dose prefilled syringe: A syringe pre-loaded with the medication for one-time use. A higher-concentration version, Eylea HD, is also available as a solution in a single-dose vial.

Question 1

What is Eylea?

Accepted Answer

Eylea contains the active ingredient aflibercept, which belongs to a class of medications known as vascular endothelial growth factor (VEGF) inhibitors. This therapy works by binding to specific proteins in the body that trigger the development of new, fragile blood vessels.

By interfering with these proteins, the medication helps to address biological processes that lead to vessel growth and fluid accumulation. This action is intended to help maintain the health of the eye and support visual function.

Question 2

What is Eylea used for?

Accepted Answer

Eylea is used to treat:

Neovascular age-related macular degeneration
Macular edema
Diabetic retinopathy

Question 3

How does Eylea work?

Accepted Answer

Blocking Abnormal Vessel Growth

Eylea belongs to a class of medications known as vascular endothelial growth factor (VEGF) inhibitors. In certain eye conditions, the body produces high levels of a protein called VEGF. This protein signals the body to create new blood vessels. However, in the eye, these new vessels are often weak and abnormal.

These abnormal vessels can leak blood and fluid into the retina, which is the light-sensitive tissue at the back of the eye. This leakage causes swelling and damage, leading to vision loss.

The Decoy Mechanism

Eylea acts as a decoy receptor or a trap for specific proteins in the eye. It specifically targets and binds to:

VEGF-A: The primary protein responsible for new blood vessel growth and increased vascular permeability.
PlGF (Placental Growth Factor): Another protein that contributes to the growth of abnormal blood vessels and inflammation.

When Eylea binds to these proteins, it prevents them from attaching to their natural receptors on the surface of blood vessel cells. Because the proteins are trapped, they cannot send the signal to grow new vessels or cause existing ones to leak.

Reducing Swelling and Fluid

By blocking these signals, Eylea helps to:

Decrease the amount of fluid and swelling (edema) in the retina.
Prevent the formation of new, fragile blood vessels.
Stop existing abnormal vessels from leaking.

This process helps to stabilize vision and, in many cases, can lead to an improvement in sight by clearing the fluid that interferes with the retina's function.

Question 4

What are the active ingredients in Eylea?

Accepted Answer

The active ingredient in Eylea is aflibercept.

Question 5

What are the side effects of Eylea?

Accepted Answer

Common side effects of Eylea may include:

eye pain
conjunctival hemorrhage
vitreous floaters

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Eylea?

Accepted Answer

Eylea belongs to the VEGF inhibitor drug class.

Question 7

What is the dosage of Eylea and how do I take it?

Accepted Answer

How Eylea is Administered

Eylea is given as an intravitreal injection, which means it is injected directly into the vitreous (the jelly-like substance) of the eye. This procedure is performed by a healthcare professional, such as an ophthalmologist, in a clinical setting.

Before the injection, your doctor will use local anesthesia to numb the eye and may use antiseptic eye drops to help prevent infection. You may feel some pressure during the procedure, but the numbing medication helps minimize discomfort.

Typical Dosing Schedule

The frequency of injections depends on the specific eye condition being treated and how well you respond to the medication. In many cases, treatment begins with a series of injections given once every few weeks. After this initial phase, the time between injections may be extended to a maintenance schedule.

Your healthcare provider will determine the best schedule for you based on regular eye examinations and imaging tests to monitor the health of your retina.

Missed Doses

If you miss an appointment for your injection, contact your doctor's office as soon as possible to reschedule. Maintaining a consistent treatment schedule is important for managing your condition effectively.

Question 8

Is Eylea safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is not known if Eylea will harm an unborn baby, as there are no adequate and well-controlled studies in pregnant women. However, animal studies involving high doses of the medication administered intravenously showed evidence of embryo-fetal toxicity, including birth defects and pregnancy loss. While the dose used in human eye injections is much lower, the potential risk to a fetus cannot be ruled out.

Because of these potential risks, healthcare providers typically recommend that individuals who can become pregnant use effective birth control to prevent pregnancy. Contraception should be used:

Before the first injection.
During the entire course of treatment.
For at least 3 months after the final injection of Eylea.

If you become pregnant while receiving this medication, notify your healthcare provider immediately to discuss the risks and benefits of continuing treatment.

Breastfeeding

It is unknown whether Eylea passes into human breast milk or if it could affect a nursing infant. Because many drugs are excreted in human milk and there is a potential for serious adverse reactions in the infant, a decision must be made whether to discontinue breastfeeding or discontinue the drug. This decision should be made in consultation with a doctor, taking into account the importance of the medication to the mother's health.

Question 9

What forms and strengths does Eylea come in?

Accepted Answer

Available Forms

Eylea is a sterile solution intended for intravitreal injection, which is a procedure where the medication is injected directly into the eye by a healthcare provider.

The medication is provided in the following forms:

Single-dose vial: A vial containing the solution for one-time use.
Single-dose prefilled syringe: A syringe pre-loaded with the medication for one-time use.

A higher-concentration version, Eylea HD, is also available as a solution in a single-dose vial.

Question 10

What is the FDA approval status of Eylea?

Accepted Answer

The U.S. Food and Drug Administration (FDA) first approved Eylea (aflibercept) in 2011. It is currently approved for the treatment of the following conditions:

Neovascular (Wet) Age-Related Macular Degeneration (AMD): A condition where abnormal blood vessels grow under the retina and leak fluid.
Macular Edema following Retinal Vein Occlusion (RVO): Swelling of the retina caused by a blockage in the veins that carry blood away from the retina.
Diabetic Macular Edema (DME): Swelling in the retina that occurs in people with diabetes.
Diabetic Retinopathy (DR): Damage to the blood vessels in the retina caused by diabetes.
Retinopathy of Prematurity (ROP): An eye disease that can occur in premature babies.

Eylea does not currently have a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program. However, the FDA-approved labeling includes important safety information regarding potential risks associated with the injection procedure and the medication itself.

Regulatory guidelines require that Eylea be administered only by a qualified healthcare professional, typically an ophthalmologist, in a controlled clinical setting. This ensures proper monitoring for immediate side effects, such as increased pressure within the eye or rare but serious infections like endophthalmitis. The FDA also monitors reports of arterial thromboembolic events, such as nonfatal stroke or heart attack, which have been observed in clinical trials of VEGF inhibitors.

Question 11

What should I know about Eylea and cost?

Accepted Answer

Factors Influencing Cost

The total price of treatment with Eylea is determined by several variables, including your specific diagnosis and the treatment schedule prescribed by your doctor. Because Eylea must be administered by a healthcare professional in a medical office or clinic, the total cost typically includes the price of the medication plus fees for the injection procedure and the office visit.

Insurance and Medicare Coverage

Most insurance plans, including Medicare Part B, generally cover Eylea when it is determined to be medically necessary. Because it is an injection given by a provider rather than a drug you pick up at a pharmacy, it is usually processed through medical insurance rather than a prescription drug plan. Patients may still be responsible for deductibles, coinsurance, or copayments depending on their specific policy.

Financial Assistance

Financial support options may be available to help reduce out-of-pocket expenses:

Copay Assistance: Patients with commercial (private) insurance may qualify for copay cards or programs offered by the manufacturer to lower their share of the cost.
Patient Assistance Programs: For individuals who are uninsured or have limited income, programs may exist to provide the medication at a reduced cost or for free if eligibility requirements are met.

Biosimilar Availability

The FDA has approved biosimilar versions of aflibercept. These medications are highly similar to Eylea and are intended to provide the same clinical benefits. The introduction of biosimilars may offer lower-cost alternatives for patients and healthcare systems, though their availability and coverage can vary by insurance provider.

Eylea

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Eylea

Hospitals.net Disclosure